Navigation Links
ConvaTec Launches Versiva(R) XC(R) Campaign and Best Practice Statement

SKILLMAN, N.J., Aug. 7 /PRNewswire/ -- ConvaTec, a world-leading provider of innovative medical technologies for community and hospital care, today announced the launch of a new campaign and best practice statement supporting Versiva((R)) XC((R)) gelling foam dressing.

Backed up by extensive in vivo and in vitro data, the new campaign shows how healthcare professionals can "Expect More" with Versiva((R)) XC((R)) dressing. The only cover dressing to contain ConvaTec's proprietary Hydrofiber((R)) Technology, Versiva((R)) XC((R)) dressing transforms wounds through its unique gelling action. This action enables dressings containing Hydrofiber((R)) Technology to lock in exudate(1)(a) and its harmful components(2)(a)( )and contour closely to the wound bed,(3)(a) in response to changing wound conditions.

"Because Versiva((R)) XC((R)) is powered by Hydrofiber((R) )Technology, patients and healthcare professionals can expect more healing with this transformational dressing," said Michael Steadman, President of ConvaTec Wound Therapeutics. "Versiva((R)) XC((R)) dressing not only provides cover and comfort, it also creates an optimal moist wound environment that kick starts healing."(4)

Outlining proposed minimum standards for wound care, the Best Practice Statement: Optimizing the use of Versiva((R)) XC((R)) gelling foam dressing was developed by a panel of wound care experts in collaboration with Wounds UK, with financial support from ConvaTec. Selected excerpts will be distributed as a supplement in the August 2009 issues of Ostomy Wound Management and Today's Wound Clinic, and the document also can be downloaded at The expert recommendations are intended to provide appropriate guidance in an accessible format to help healthcare professionals manage patients.(5)

When developing the Best Practice Statement, the authors conducted an extensive literature review and a retrospective evaluation of 50 patients with wounds of various types that were managed using Versiva((R)) XC((R)) dressing. In two multicenter clinical studies, Versiva((R)) XC((R)) dressing demonstrated clinical efficacy within protocols of care managing chronic wounds such as venous leg ulcers(4) and pressure ulcers.(6) In the study in patients with venous leg ulcers, there was a significant reduction (p<0.001) in mean wound area, by 50 percent, in four weeks from baseline.(4)(b)

In a retrospective analysis using data from two previous clinical trials, healing rates at 4 weeks were found to be powerful predictors of complete wound healing at 12 weeks.(7)

Advanced Wound Dressings with Hydrofiber((R)) Technology from ConvaTec

ConvaTec dressings with Hydrofiber((R)) Technology gel on contact with fluid, providing clinicians and patients with substantial wound care benefits. This transformational technology, unique to ConvaTec, powers the performance of advanced wound care products, including AQUACEL((R)), AQUACEL((R)) Ag, and Versiva((R)) XC((R)) dressings, each developed for different wound management needs.

AQUACEL((R)) and AQUACEL((R)) Ag dressings are soft, absorbent non-woven wound dressings based on Hydrofiber((R)) Technology. Indicated for a wide range of moderate-to-highly exuding chronic and acute wounds, AQUACEL((R)) and AQUACEL((R)) Ag dressings come in a variety of shapes, sizes and formats. AQUACEL((R)) Ag dressing also provides the broad-spectrum antimicrobial properties of ionic silver, which kills a broad range of pathogens in the dressing, including MRSA and vancomycin-resistant enterococci (VRE).(8)

Versiva((R)) XC((R) )dressing provides all the benefits of Hydrofiber((R)) Technology plus a waterproof backing that acts as a barrier( )against bacteria and viral pathogens, including HIV and Hepatitis.(c,d) ( )The unique properties of Versiva((R)) XC((R) )dressing help progress wounds toward healing.(4) Indicated for use with moderately-to-highly exuding chronic and acute wounds, because it includes Hydrofiber((R) )Technology, Versiva((R)) XC((R) )dressing is also the only dressing designed specifically to cover AQUACEL((R)) and AQUACEL((R)) Ag dressings.

ConvaTec( )dressings containing Hydrofiber((R)) Technology have been evaluated in numerous clinical trials across a range of chronic and acute wounds, including pressure ulcers, leg ulcers, diabetic foot ulcers, partial thickness (second degree) burns and surgical incisions.

About ConvaTec

ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key business divisions - Ostomy Care, Wound Therapeutics, Continence and Critical Care and Infusion Devices - ConvaTec products support health care professionals from the hospital to the community health setting. From its headquarters in Skillman, New Jersey, the company oversees more than 8,000 employees in over 90 countries serving consumers and their health care professionals on six continents. For more information, please visit

(a)( )as demonstrated in vitro

(b)( )using protocols of care that included Versiva((R)) XC((R)) gelling foam dressing with sustained graduated compression bandages

(c) provided the dressing remains intact and without leakage. The use of this dressing neither guarantees nor warrantees against AIDS or Hepatitis virus transmission.

(d)( )use waterproof tape to secure the edges of non-adhesive dressing or dressings that have been cut across the central area

  1. Griffiths B, Adams S, Kelly S, Shaw H. Retention of fluid and lateral spread in a new gelling foam dressing versus other foam dressings. Poster presented at: 20th Annual Symposium on Advanced Wound Care and the Wound Healing Society Meeting; April 28-May 1, 2007; Tampa, FL.
  2. Newman GR, Walker M, Hobot J, Bowler P. Visualisation of bacterial sequestration and bactericidal activity within hydrating Hydrofiber((R)) wound dressings. Biomaterials. 2006;27(7):1129-1139.
  3. Jones SA, Bowler PG, Walker M. Antimicrobial activity of silver-containing dressings is influenced by dressing conformability with a wound surface. Wounds. 2005;17(9):263-270.
  4. Vanscheidt W, Munter KC, Klovekorn W, Vin F, Gauthier JP, Ukat A. A prospective study on the use of a non-adhesive gelling foam dressing on exuding leg ulcers. J Wound Care. 2007;16(6):261-265.
  5. Wounds UK. Best Practice Statement: Optimising the use of Versiva((R)) XC((R)) gelling foam dressing. Aberdeen, Wounds UK, 2009. Accessed July 28, 2009.
  6. Parish LC, Dryski M, Cadden S. Prospective clinical study of a new adhesive gelling foam dressing in pressure ulcers. Int Wound J. 2008;5:60-67.
  7. Cardinal M, Eisenbud D, Phillips T, Harding K. Early healing rates and wound area measurements are reliable predictors of later complete wound closure. Wound Repair Regen. 2008;16: 19-22.
  8. Bowler PG, Jones SA, Walker M, Parsons D. Microbicidal properties of a silver-containing Hydrofiber((R)) dressing against a variety of burn wound pathogens. J Burn Care Rehabil. 2004;25(2):192-196.

Hydrofiber, AQUACEL, Versiva and XC are registered trademarks of ConvaTec Inc.

(C) 2009 ConvaTec Inc.



    Punnie Donohue                       Courtney Judd
    ConvaTec                             Weber Shandwick
    Phone: (908) 904-2151                Phone: (212) 445-8365

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ConvaTec Launches Hydrofiber(R) Technology Web Site
2. ConvaTec Launches New Programs to Support and Recognize WOC Nursing
3. Prospective Evaluation Finds High Levels of Satisfaction with ConvaTec Moldable Skin Barrier
4. ConvaTec Launches New AQUACEL(R) Ag Dressing with Strengthening Fiber
5. ConvaTec and HemCon Announce Co-Promotion Agreement
6. ConvaTec Names Paul Moraviec President, Continence and Critical Care Business Unit and ConvaTec EMEA Region
7. ConvaTec Announces Divestiture of Unomedical Wound Care and Ophthalmics Business
8. ConvaTec Announces Expanded Indications for AQUACEL(R) and AQUACEL(R) Ag Dressings in Management of Surgical Wounds
9. ConvaTec Launches New Lifestyle Magazine for People With an Ostomy
10. ConvaTec Names Presidents of Wound Therapeutics and Ostomy Care Business Units
11. ConvaTec Launches SUR-FIT Natura(R) Low-Pressure Adaptor
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... has been selected as a finalist in this year’s Fierce Innovation Awards: Healthcare ... IT Healthcare was recognized as a finalist in the category of Digital Solutions ...
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 /PRNewswire/ -- Royal Philips  ... an X-ray imaging software that produces high-contrast images for ... use a grid, at the 2015 Radiological Society ... SkyFlow is Philips, first digital imaging solution providing grid-like ... improves clinician,s workflow and supports "first-time-right imaging" by decreasing ...
(Date:12/1/2015)... 1, 2015 A federal court has denied the ... a lawsuit filed by the Pharmaceutical Care Management Association (PCMA) ... a new law that forces employers and consumers to pay ... Arkansas must now defend a law that raises ... and CEO Mark Merritt . --> ...
(Date:12/1/2015)... 2015 --> --> ... Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, ... Pipeline Analysis - Global Forecast to 2020", published by MarketsandMarkets, ... 73,529.2 Million by 2020 from USD 40,281.6 Million in 2015, ... Browse 37 market data T ...
Breaking Medicine Technology: